

**Ref:** EPL/CS/SE/0030/2025**Date:** May 22, 2025

To,

<b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	<b>BSE Limited</b> P J Towers, Dalal Street, Mumbai- 400 001
<b>Script Symbol: EMCURE</b>	<b>Scrip Code/Symbol: 544210/ EMCURE</b>

Dear Sir/Madam,

**Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Re-appointment of Dr. Mukund Gurjar as a Whole-time Director of the Company**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), read with Schedule III of aforesaid regulation and SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November, 2024 we would like to inform that, based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on May 22, 2025, has approved the re-appointment of Dr. Mukund Gurjar (DIN: 00026843) as Whole-time Director of the Company for a further period of one (1) year commencing from August 28, 2025, subject to approval of Members in the ensuing Annual General Meeting of the Company.

The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are provided in **Annexure A**, enclosed herewith.

You are requested to take the above information on your records.

Thanking you,

**For Emcure Pharmaceuticals Limited**

**Chetan Sharma**  
**Company Secretary & Compliance Officer**  
**Membership Number: F8352**

**Encl.:** As above

**Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

**Annexure-A**

**Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Information</b>
1	Reason for change viz. <del>appointment, re-appointment, resignation, removal, death or otherwise</del>	Re-appointment as Whole-time Director of the Company.
2	Date of <del>appointment/</del> re-appointment/cessation (as applicable) & term of <del>appointment/</del> re-appointment	Re-appointment with effect from August 28, 2025 for a further period of one (1) year, subject to approval of Members of the Company.
3	Brief profile (in case of appointment);	<p>Dr. Mukund Gurjar has been associated with the Company since July 23, 2001, as Director of the Company. Dr. Gurjar holds a bachelor's degree in science, a master's degree in science and qualified as a doctor of philosophy in the faculty of science from the Nagpur University. He also holds a degree of doctor of philosophy from the Queen Elizabeth College, University of London Prior to joining our Company, he was working with the National Chemical Laboratory, Pune for 24 years. He has received a certificate of appreciation in recognition of 17 years of his valued services as an editorial advisory board member for Organic Process Research &amp; Development, American Chemical Society.</p> <p>Dr. Gurjar brings technical &amp; industrial expertise to the Board as well as the Company. He has been an Executive Director and Chief Scientific Officer of the Company.</p>
4	Disclosure of relationships between Directors (in case of appointment of a director).	Dr. Gurjar is not related to any director on the Board of the Company.

**Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251